Search

Displaying results 851 - 860 of 3917 in total
  1. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536] … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.

  2. Drug

    Multipotent adult arogenitor cells

    go.drugbank.com/drugs/DB15742
    Investigational

    Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. … They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic.

  3. Drug

    Sevelamer

    go.drugbank.com/drugs/DB00658
    ApprovedInvestigational

    Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.

  4. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. … In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

    Categories: Non-Selective Monoamine Reuptake Inhibitors
  5. Drug

    Nadroparin

    go.drugbank.com/drugs/DB08813
    ApprovedInvestigationalWithdrawn

    Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin...

  6. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, imipenem, is one ...

  7. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … CGRP receptors are expressed in the central and peripheral nervous system; however, CGRP does not cross the blood-brain barrier, suggesting that it acts on peripheral nerves.

  8. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    PIK3CA is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown...

  9. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. … Gadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels.